Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
MD Young Rock Jang, MD Yoon Ju Oh, MD, MPH Jin Yong Kim
Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100675
Background: In a Phase III study, regdanvimab (CT-P59) reduced the risk of hospitalization or death versus placebo in patients with mild-to-moderate coronavirus disease 2019 (COVID-19). Purpose: We performed a retrospective cohort study of patients with COVID-19 to examine the effect of regdanvimab versus standard of care (SoC) on oxygen saturation. Methods: We reviewed patients with mild-to-moderate COVID-19 confirmed by reverse transcriptionpolymerase chain reaction at a single hospital in the Republic of Korea. The primary efficacy end point was the proportion of patients deteriorating with peripheral capillary oxygen saturation < 94% on room air up to day 28. Results: A total of 127 patients were treated for COVID-19 with regdanvimab, 190 with SoC. The proportion of patients deteriorating with peripheral capillary oxygen saturation < 94% on room air up to day 28 was 13.4% with regdanvimab and 39.5% with SoC ( P < 0.0 0 01); median time (range) until sustained recovery of fever was 2.0 (0.2-14.8) and 4.2 (0.1-17.1) days, respectively. Supplemental oxygen was required by 23.6% of patients with regdanvimab and 52.1% with SoC ( P < 0.0 0 01) for a mean of 6.3 and 8.7 days, respectively ( P = 0.0113); no patients needed mechanical ventilation. Compared with SoC, hospitalization was shorter with regdanvimab (mean = 11.1 vs 13.6 days; 63.8% vs 31.6% discharged within 11 days; both P values < 0.0 0 01). Fewer regdanvimab-treated patients required remdesivir (14.2% vs 43.2%; P < 0.0 0 01). There were no deaths. Two patients had adverse reactions with regdanvimab. Conclusions: This real-world study indicates that regdanvimab can prevent deterioration in patients with mild-to-moderate COVID-19. (
Conflicts of Interest Statement The authors have indicated that they have no conflicts of interest regarding the content of this article.
References
Alam, Mahmud, Aggarwal, Clinical impact of the early use of monoclonal antibody LY-CoV555 (bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study, Cureus
Baraniuk, Where are we with drug treatments for covid-19?, BMJ
Berlin, Gulick, Martinez, Severe Covid-19, N Engl J Med
Bierle, Ganesh, Wilker, Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high--risk patients with mild-moderate COVID-19, J Prim Care Community Health
Brouqui, Amrane, Million, Asymptomatic hypoxia in COVID-19 is associated with poor outcome, Int J Infect Dis
Chen, Feng, Xu, Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to Mar 2020: a multi-center, retrospective cohort study in China, Front Med
Corti, Purcell, Snell, Veesler, Tackling COVID-19 with neutralizing monoclonal antibodies, Cell
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Gupta, Marks, Samuels, Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study, Eur Respir J
Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther
Kumar, Wu, Stosor, Real-world experience of bamlanivimab for COVID-19: a case-control study, Clin Infect Dis
Marston, Paules, Fauci, Monoclonal antibodies for emerging infectious diseases -borrowing from history, N Engl J Med
Rechtman, Curtin, Navarro, Nirenberg, Horton, Vital signs assessed in initial clinical encounters predict COVID-19 mortality in an NYC hospital system, Sci Rep
Ryu, Kang, Noh, The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2, Biochem Biophys Res Commun
Ryu, Song, Kim, Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant, Biochem Biophys Res Commun
Sandulsecu, Therapeutic effect of regdanvimab in patients with mild to moderate COVID-19: day 28 results from a multi-centre, randomised, controlled pivotal trial
Sanitária -Anvisa, Anvisa autoriza uso emergencial de novo medicamento para Covid-19
Syed, Regdanvimab: First Approval, Drugs
Venkatesan, Repurposing drugs for treatment of COVID-19, Lancet Respir Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Wouters, Shadlen, Salcher-Konrad, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, Lancet
Zhai, Luo, Zheng, Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study, Sci Rep
Zhang, Wang, Zhao, The clinical characteristics and prognosis factors of mild-moderate patients with COVID-19 in a mobile cabin hospital: a retrospective, single-center study, Front Public Health